Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Valeo Chalks Up Another Milestone For Canadian Enoxaparin Biosimilars

Follows Backing To Be Listed On The Quebec Public Health Plan

Executive Summary

Canada’s Valeo Pharma insists it has “worked tirelessly to ensure a robust supply of Redesca,” after completing another milestone for the company’s enoxaparin biosimilar product.

You may also be interested in...



Enoxaparin Biosimilar Makes It Six For Sandoz Canada

Sandoz Canada has taken another “important step as we pursue our ambition to become the leading biosimilars and generics company” with the launch of biosimilar enoxaparin.

Valeo Pharma To Launch Enoxaparin In Canada Early Next Year

Canadian firm Valeo Pharma is looking to make a splash with enoxaparin biosimilars, Redesca and Redesca HP, following approval from Health Canada.

What’s Next? Five Things To Look Out For In October

A busy October will include planned biosimilar launches and key appointments for the off-patent sector.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150809

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel